Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

No cause for panic over H1N1; current strains in circulation since 2025, says ICMR

The scientists, as per the ICMR press note, also clarified that the influenza strains currently circulating are well matched with the vaccine strains recommended for the Northern Hemisphere.

No cause for panic over H1N1; current strains in circulation since 2025, says ICMR

New Delhi: A senior Indian Council of Medical Research (ICMR) scientist has reassured the public that there is no need for alarm over the current influenza A (H1N1) viruses circulating in India. These viruses are identical to the A/Missouri/11/2025 (H1N1) pdm09-like strain and have been present since 2025. The viruses belong to clade 6B.1A.5a2a and subclade D.3.1.1.

They have been assessed as being well-matched with the recommended vaccine strains for the Northern Hemisphere. Seasonal influenza, including H1N1, is generally mild and self-limiting, with common symptoms of fever, cough, headache, and body aches. Most individuals recover with proper care and rest. However, young children, the elderly, and those with pre-existing health issues may face a higher risk of complications.

The ICMR is closely monitoring the situation through regular surveillance and implementing necessary public health measures. The government is urging people to seek medical attention if symptoms persist, worsen, or become severe. The situation is being closely monitored, and public health measures are being undertaken to ensure the well-being of the population.

Written by urgent.news from ETHealthworld's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at health.economictimes.indiatimes.com →

More in Health & Medicine

Moderna-Merck cancer vaccine success marks breakthrough for personalised mRNA treatment

A PERSONALISED mRNA-based cancer vaccine developed by Moderna and Merck & Co. has delivered a landmark result in a late-stage melanoma trial, strengthening hopes that technology originally propelled into the mainstream by Covid-19 vaccines could even...

  • Moderna and Merck's personalized mRNA cancer vaccine shows success in melanoma trial.
  • Vaccine reduces melanoma recurrence in post-surgery patients.
  • Treatment identifies and incorporates up to 34 tumor-specific mutations.

More from Monday 24 August →